|
1
|
Schettini F, Giuliano M, De Placido S and
Arpino G: Nab-paclitaxel for the treatment of triple-negative
breast cancer: Rationale, clinical data and future perspectives.
Cancer Treat Rev. 50:129–141. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wan Y, Huang A, Yang Y, Xie G, Chen X, Hu
J, Chen X, Yang L, Li J, Chen L, et al: A vector-based short
hairpin RNA targeting Aurora A inhibits breast cancer growth. Int J
Oncol. 36:1121–1128. 2010.PubMed/NCBI
|
|
3
|
Chen S, Dong Q, Hu S, Cai J, Zhang W, Sun
J, Wang T, Xie J, He H, Xing J, et al: Proteomic analysis of the
proteins that are associated with the resistance to paclitaxel in
human breast cancer cells. Mol Biosyst. 10:294–303. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lu J, Tan M, Huang WC, Li P, Guo H, Tseng
LM, Su XH, Yang WT, Treekitkarnmongkol W, Andreeff M, et al:
Mitotic deregulation by survivin in ErbB2-overexpressing breast
cancer cells contributes to Taxol resistance. Clin Cancer Res.
15:1326–1334. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lai D, Ho KC, Hao Y and Yang X: Taxol
resistance in breast cancer cells is mediated by the hippo pathway
component TAZ and its downstream transcriptional targets Cyr61 and
CTGF. Cancer Res. 71:2728–2738. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lens SM, Voest EE and Medema RH: Shared
and separate functions of polo-like kinases and aurora kinases in
cancer. Nat Rev Cancer. 10:825–841. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mountzios G, Terpos E and Dimopoulos MA:
Aurora kinases as targets for cancer therapy. Cancer Treat Rev.
34:175–182. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zou Z, Yuan Z, Zhang Q, Long Z, Chen J,
Tang Z, Zhu Y, Chen S, Xu J, Yan M, et al: Aurora kinase A
inhibition-induced autophagy triggers drug resistance in breast
cancer cells. Autophagy. 8:1798–1810. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Terakawa T, Miyake H, Kumano M and
Fujisawa M: Growth inhibition and enhanced chemosensitivity induced
by down-regulation of Aurora-A in human renal cell carcinoma Caki-2
cells using short hairpin RNA. Oncol Lett. 2:713–717.
2011.PubMed/NCBI
|
|
10
|
Li Y, Tang K, Zhang H, Zhang Y, Zhou W and
Chen X: Function of Aurora kinase A in Taxol-resistant breast
cancer and its correlation with P-gp. Mol Med Rep. 4:739–746.
2011.PubMed/NCBI
|
|
11
|
Bergstralh DT, Taxman DJ, Chou TC,
Danishefsky SJ and Ting JP: A comparison of signaling activities
induced by Taxol and desoxyepothilone B. J Chemother. 16:563–576.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li W, Liu J, Jackson K, Shi R and Zhao Y:
Sensitizing the therapeutic efficacy of taxol with shikonin in
human breast cancer cells. PLoS One. 9:e940792014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang Q, Si S, Schoen S, Chen J, Jin XB
and Wu G: Suppression of autophagy enhances preferential toxicity
of paclitaxel to folliculin-deficient renal cancer cells. J Exp
Clin Cancer Res. 32:992013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang NN, Zhao LJ, Wu LN, He MF, Qu JW,
Zhao YB, Zhao WZ, Li JS and Wang JH: Mechanistic analysis of
taxol-induced multidrug resistance in an ovarian cancer cell line.
Asian Pac J Cancer Prev. 14:4983–4988. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu R, Nakano K, Iwasaki H, Kumagai M,
Wakabayashi R, Yamasaki A, Suzuki H, Mibu R, Onishi H and Katano M:
Dual blockade of phosphatidylinositol 3-kinase and
mitogen-activated protein kinase pathways overcomes
paclitaxel-resistance in colorectal cancer. Cancer Lett.
306:151–160. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Le XF and Bast RC Jr: Src family kinases
and paclitaxel sensitivity. Cancer Biol Ther. 12:260–269. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liao CH, Sang S, Ho CT and Lin JK:
Garcinol modulates tyrosine phosphorylation of FAK and subsequently
induces apoptosis through down-regulation of Src, ERK, and Akt
survival signaling in human colon cancer cells. J Cell Biochem.
96:155–169. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Qin B, Ariyama H, Baba E, Tanaka R, Kusaba
H, Harada M and Nakano S: Activated Src and Ras induce gefitinib
resistance by activation of signaling pathways downstream of
epidermal growth factor receptor in human gallbladder
adenocarcinoma cells. Cancer Chemother Pharmacol. 58:577–584. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gan PP, Pasquier E and Kavallaris M: Class
III beta-tubulin mediates sensitivity to chemotherapeutic drugs in
non small cell lung cancer. Cancer Res. 67:9356–9363. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li Y, Tang K, Zhang L, Li C, Niu F, Zhou
W, Yang H, Feng Z and Chen X: The molecular mechanisms of a novel
multi-kinase inhibitor ZLJ33 in suppressing pancreatic cancer
growth. Cancer Lett. 356:392–403. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li Y, Zhou W, Wei L, Jin J, Tang K, Li C,
Teh BT and Chen X: The effect of Aurora kinases on cell
proliferation, cell cycle regulation and metastasis in renal cell
carcinoma. Int J Oncol. 41:2139–2149. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li Y, Zhang ZF, Chen J, Huang D, Ding Y,
Tan MH, Qian CN, Resau JH, Kim H and Teh BT: VX680/MK-0457, a
potent and selective Aurora kinase inhibitor, targets both tumor
and endothelial cells in clear cell renal cell carcinoma. Am J
Transl Res. 2:296–308. 2010.PubMed/NCBI
|
|
23
|
Do TV, Xiao F, Bickel LE, Klein-Szanto AJ,
Pathak HB, Hua X, Howe C, OBrien SW, Maglaty M, Ecsedy JA, et al:
Aurora kinase A mediates epithelial ovarian cancer cell migration
and adhesion. Oncogene. 33:539–549. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mendiola M, Barriuso J, Mariño-Enríquez A,
Redondo A, Domínguez-Cáceres A, Hernández-Cortés G, Pérez-Fernández
E, Sánchez-Navarro I, Vara JA, Suárez A, et al: Aurora kinases as
prognostic biomarkers in ovarian carcinoma. Hum Pathol. 40:631–638.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kawaguchi W, Itamochi H, Kigawa J,
Kanamori Y, Oishi T, Shimada M, Sato S, Shimogai R, Sato S and
Terakawa N: Simultaneous inhibition of the mitogen-activated
protein kinase kinase and phosphatidylinositol 3-kinase pathways
enhances sensitivity to paclitaxel in ovarian carcinoma. Cancer
Sci. 98:2002–2008. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Knuefermann C, Lu Y, Liu B, Jin W, Liang
K, Wu L, Schmidt M, Mills GB, Mendelsohn J and Fan Z:
HER2/PI-3K/Akt activation leads to a multidrug resistance in human
breast adenocarcinoma cells. Oncogene. 22:3205–3212. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li JP, Yang YX, Liu QL, Pan ST, He ZX,
Zhang X, Yang T, Chen XW, Wang D, Qiu JX, et al: The
investigational Aurora kinase A inhibitor alisertib (MLN8237)
induces cell cycle G2/M arrest, apoptosis, and autophagy via p38
MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
Drug Des Devel Ther. 9:1627–1652. 2015.PubMed/NCBI
|
|
28
|
Wang X, Lu N, Niu B, Chen X, Xie J and
Cheng N: Overexpression of Aurora-A enhances invasion and matrix
metalloproteinase-2 expression in esophageal squamous cell
carcinoma cells. Mol Cancer Res. 10:588–596. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gan PP, McCarroll JA, Pouha ST, Kamath K,
Jordan MA and Kavallaris M: Microtubule dynamics, mitotic arrest,
and apoptosis: Drug-induced differential effects of
betaIII-tubulin. Mol Cancer Ther. 9:1339–1348. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Almhanna K, Cubitt CL, Zhang S, Kazim S,
Husain K, Sullivan D, Sebti S and Malafa M: MK-2206, an Akt
inhibitor, enhances carboplatinum/paclitaxel efficacy in gastric
cancer cell lines. Cancer Biol Ther. 14:932–936. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Clark AS, West K, Streicher S and Dennis
PA: Constitutive and inducible Akt activity promotes resistance to
chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol
Cancer Ther. 1:707–717. 2002.PubMed/NCBI
|
|
32
|
Chen J, Huang D, Rubera I, Futami K, Wang
P, Zickert P, Khoo SK, Dykema K, Zhao P, Petillo D, et al:
Disruption of tubular Flcn expression as a mouse model for renal
tumor induction. Kidney Int. 88:1057–1069. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wu M, Si S, Li Y, Schoen S, Xiao GQ, Li X,
Teh BT, Wu G and Chen J: Flcn-deficient renal cells are tumorigenic
and sensitive to mTOR suppression. Oncotarget. 6:32761–32773. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gutiérrez-González A, Belda-Iniesta C,
Bargiela-Iparraguirre J, Dominguez G, Alfonso García P, Perona R
and Sanchez-Perez I: Targeting Chk2 improves gastric cancer
chemotherapy by impairing DNA damage repair. Apoptosis. 18:347–360.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Haruki K, Shiba H, Fujiwara Y, Furukawa K,
Iwase R, Uwagawa T, Misawa T, Ohashi T and Yanaga K: Inhibition of
nuclear factor-κB enhances the antitumor effect of paclitaxel
against gastric cancer with peritoneal dissemination in mice. Dig
Dis Sci. 58:123–131. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Qiu H, Yashiro M, Zhang X, Miwa A and
Hirakawa K: A FGFR2 inhibitor, Ki23057, enhances the
chemosensitivity of drug-resistant gastric cancer cells. Cancer
Lett. 307:47–52. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
George JA, Chen T and Taylor CC: SRC
tyrosine kinase and multidrug resistance protein-1 inhibitions act
independently but cooperatively to restore paclitaxel sensitivity
to paclitaxel-resistant ovarian cancer cells. Cancer Res.
65:10381–10388. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ding YH, Zhou ZW, Ha CF, Zhang XY, Pan ST,
He ZX, Edelman JL, Wang D, Yang YX, Zhang X, et al: Alisertib, an
Aurora kinase A inhibitor, induces apoptosis and autophagy but
inhibits epithelial to mesenchymal transition in human epithelial
ovarian cancer cells. Drug Des Devel Ther. 9:425–464.
2015.PubMed/NCBI
|
|
39
|
Puls LN, Eadens M and Messersmith W:
Current status of SRC inhibitors in solid tumor malignancies.
Oncologist. 16:566–578. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wheeler DL, Iida M and Dunn EF: The role
of Src in solid tumors. Oncologist. 14:667–678. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pengetnze Y, Steed M, Roby KF, Terranova
PF and Taylor CC: Src tyrosine kinase promotes survival and
resistance to chemotherapeutics in a mouse ovarian cancer cell
line. Biochem Biophys Res Commun. 309:377–383. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen T, Pengetnze Y and Taylor CC: Src
inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells
by caspase-9-independent activation of caspase-3. Mol Cancer Ther.
4:217–224. 2005.PubMed/NCBI
|
|
43
|
Kim SH, Juhnn YS and Song YS: Akt
involvement in paclitaxel chemoresistance of human ovarian cancer
cells. Ann N Y Acad Sci. 1095:82–89. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Fu J, Bian M, Jiang Q and Zhang C: Roles
of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res.
5:1–10. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Long M, Yin G, Liu L, Lin F, Wang X, Ren
J, Wei J, Dong K and Zhang H: Adenovirus-mediated Aurora A shRNA
driven by stathmin promoter suppressed tumor growth and enhanced
paclitaxel chemotherapy sensitivity in human breast carcinoma
cells. Cancer Gene Ther. 19:271–281. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Marshall CJ: MAP kinase kinase kinase, MAP
kinase kinase and MAP kinase. Curr Opin Genet Dev. 4:82–89. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tseng YS, Lee JC, Huang CY and Liu HS:
Aurora-A overexpression enhances cell-aggregation of Ha-ras
transformants through the MEK/ERK signaling pathway. BMC Cancer.
9:4352009. View Article : Google Scholar : PubMed/NCBI
|
